Article

[Corneal scar development after cross-linking in keratoconus].

Universitätsklinikum Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden.
Der Ophthalmologe (Impact Factor: 0.72). 04/2010; 107(9):837-42.
Source: PubMed

ABSTRACT Corneal scar development after riboflavin-UVA-induced corneal collagen cross-linking (CXL) was retrospectively evaluated.
A total of 163 CXL-treated eyes in 127 patients with stage 1-3 keratoconus according to Krumeich's classification were included in this retrospective analysis. The follow-up period was 1 year. At the first and at all follow-up examinations uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), biomicroscopic findings, corneal topography and corneal thickness were recorded.
At 1 year following CXL, 149 eyes (91.4%) of 114 patients had a clear cornea without corneal scar (control group), while 14 eyes (8.6%) of 13 patients developed clinically significant corneal scar (scar group). Preoperatively, the mean K value of the apex was 62.1 ± 13.8 D in the control group and 71.1 ± 13.2 D in the scar group (P=.02). The mean value of corneal thickness before the procedure was 478.1 ± 52.4 μm in the control group and 420.0 ± 33.9 μm in the scar group (P=.001). The UCVA and BCVA, which were preoperatively similar between groups (P=.59, P=.75 respectively), were postoperatively improved in the control group (P=.023, P=.001 respectively), but reduced in the scar group (P=.012, P=.004 respectively).
K-values and corneal thickness could be considered as predictive factors for the possible development of corneal scarring after riboflavin-UVA-induced CXL. Advanced keratoconus appears to be associated with a higher risk of corneal scar development due to lower corneal thickness, greater curvature and intrinsic tissue characteristics.

1 Follower
 · 
115 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review aims to assess the efficacy and safety of epithelial removal (ER) and transepithelial (TE) corneal collagen crosslinking (CXL) for the treatment of keratoconus. We used MEDLINE to identify all ER and TE CXL studies on keratoconic eyes (n≥20, follow-up ≥12 months). Ex vivo and studies for non-keratoconus indications or in conjunction with other procedures were excluded. Data on uncorrected (UDVA) and corrected (CDVA) distance visual acuity, refractive cylinder, maximum keratometry (Kmax), and adverse events were collected at the latest follow-up and 1 year. Only one randomised controlled trial (RCT) qualified inclusion. Forty-four ER and five TE studies were included. For logMAR UDVA, CDVA, mean spherical equivalent, refractive cylinder and Kmax, at latest follow-up 81, 85, 93, 62, and 93% ER studies vs 66.7, 80, 75, 33, and 40% TE studies reported improvement, respectively. Whereas at 1 year, 90, 59, and 91% ER studies vs 80, 50, and 25% TE studies reported improvement, respectively. The majority of studies showed reduced pachymetry in both groups. Treatment failure, retreatment rates, and conversion to transplantation were reported to be up to 33, 8.6, and 6.25%, respectively, in ER studies only. Stromal oedema, haze, keratitis, and scarring were only reported in ER studies, whereas endothelial cell counts remained variable in both groups. Both ER and TE studies showed improvement in visual acuity, refractive cylinder but Kmax worsened in most TE studies. Adverse events were reported more with ER studies. This review calls for more high quality ER and TE studies with comparable parameters for further assessment of safety and efficacy.Eye advance online publication, 3 October 2014; doi:10.1038/eye.2014.230.
    Eye (London, England) 10/2014; 29(1). DOI:10.1038/eye.2014.230 · 1.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Riboflavin and ultraviolet-A induced cross-linking (CXL) is a promising therapeutic option to halt the progression of keratoconus. The aim of the study was to prove a long-term stabilizing effect of riboflavin and ultraviolet-A induced collagen CXL in young and otherwise healthy patients with progressive keratoconus and a corneal thickness of at least 400 μm on average 10 years after treatment.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Beim Keratokonus handelt es sich um eine progressive, ektatische Erkrankung der Hornhaut. Bis vor wenigen Jahren konnte durch Brillen- bzw. Kontaktlinsenanpassung nur symptomatisch behandelt werden, und auch eine Keratoplastik oder intrakorneale Ringsegmente können nicht zu einer Heilung führen. Das Riboflavin-UVA-Crosslinking (CXL) kann zwar ebenfalls keine Heilung bewirken, soll aber die Progression stoppen. Das Wirkprinzip besteht in einer photochemischen Reaktion von Riboflavin und UVA-Licht, wodurch im Stroma freie Sauerstoffradikale entstehen, die zu kovalenten Verbindungen der Kollagenfibrillen führen. Diese Versteifung der Kornea soll die Progression des Keratokonus stoppen. Nach ersten Berichten Ende der 1990er-Jahre kam es in den vergangenen Jahren zu einer zunehmenden Verbreitung dieser Therapie. Zahlreiche Fallserien weisen darauf hin, dass die Progression bei manchen Patienten aufgehalten werden kann. Allerdings gibt es bisher kaum randomisierte, kontrollierte Multicenterstudien, die eine hohe Evidenz nachweisen. In diesem Beitrag soll auf die aktuelle Studienlage zur Effektivität des CXL, auf die Indikationsstellung sowie auf neue Entwicklungen eingegangen werden.
    Der Ophthalmologe 09/2013; 110(9). DOI:10.1007/s00347-013-2820-3 · 0.72 Impact Factor